Haloperidol is a typical antipsychotic. It belongs to the first generation of antipsychotic medications, which were developed before the newer “atypical” (second-generation) drugs that arrived in the 1990s. Understanding this distinction matters because the two classes work differently in the brain and carry different side effect profiles.
How Haloperidol Works
Haloperidol’s primary action is blocking dopamine receptors in the brain, specifically the D2 subtype. This is the hallmark of typical antipsychotics: strong, focused dopamine blockade. The drug reaches its peak effectiveness when about 72% of dopamine receptors are occupied. It also has some blocking activity on receptors involved in adrenaline signaling, histamine response, and the neurotransmitter acetylcholine, but dopamine remains the main target.
Atypical antipsychotics, by contrast, block both dopamine and serotonin receptors in a more balanced way. That dual action is largely what separates the two classes and explains why their side effect profiles differ.
Why the Typical vs. Atypical Distinction Matters
The practical reason people search this question is usually about side effects. Because haloperidol blocks dopamine so powerfully and selectively, it carries a higher risk of movement-related side effects, known as extrapyramidal symptoms. These include muscle stiffness, tremor, restlessness, and involuntary muscle contractions called dystonia.
The numbers bear this out clearly. In a meta-analysis covering over 3,400 patients receiving injectable antipsychotics for agitation, 4.7% of those given haloperidol alone experienced acute dystonia, compared to just 0.6% of those given a second-generation (atypical) antipsychotic. Restlessness (akathisia) followed a similar pattern: about 7.1% of haloperidol patients developed it versus 1.7% on atypical drugs.
Tardive Dyskinesia Risk
With long-term use, haloperidol also carries a meaningful risk of tardive dyskinesia, a condition involving repetitive, involuntary movements, often of the face, tongue, or jaw. These movements can sometimes persist even after the medication is stopped. Studies tracking haloperidol specifically have reported annual incidence rates ranging from about 2% to 9% per year of use. In one prospective study, the cumulative risk of tardive dyskinesia after roughly four years on conventional antipsychotics reached nearly 20%. Atypical antipsychotics carry this risk too, but at lower rates.
Metabolic Side Effects
One area where haloperidol compares favorably to some atypical antipsychotics is metabolic health. Atypical drugs like olanzapine and clozapine are associated with significant weight gain and blood sugar increases. In a network meta-analysis of 12 antipsychotics, patients on olanzapine and clozapine showed consistently higher glucose levels than those on haloperidol. That said, haloperidol didn’t show clear metabolic advantages over every atypical drug. Several newer atypicals, including ziprasidone, lurasidone, and aripiprazole, performed as well or better than haloperidol on glucose-related measures.
So the tradeoff is real: haloperidol tends to cause more movement problems but fewer metabolic issues than certain atypical antipsychotics, though not all of them.
Heart Rhythm Considerations
Haloperidol can affect the heart’s electrical timing, specifically a measurement on an ECG called the QTc interval. Prolongation of this interval raises the theoretical risk of dangerous heart rhythm problems. In one naturalistic study of hospitalized patients, about 22% of those receiving antipsychotics (including haloperidol) developed a critically prolonged QTc interval, typically within the first two days. However, the researchers noted that serious cardiac events remained rare, and the rate of critical prolongation wasn’t statistically different from the unmedicated group. Still, heart rhythm monitoring is standard practice when haloperidol is used, particularly in older adults or people with existing heart conditions.
Where Haloperidol Is Still Used
Despite being an older medication, haloperidol remains widely used. Its rapid onset and potent dopamine blockade make it a common choice for managing acute agitation, severe psychosis, and delirium in hospital settings. It is also used in chronic treatment of schizophrenia and Tourette syndrome. The availability of both oral and injectable forms adds to its versatility.
Many clinicians now prefer atypical antipsychotics as first-line treatment for conditions like schizophrenia because of the lower movement-related side effect burden. But haloperidol’s effectiveness, low cost, and decades of clinical familiarity keep it in active use, especially in acute care and in settings where newer medications aren’t available or tolerated.